Xiaozhong Chen
Tokyo Institute of Technology(JP)Guiyang Medical University(CN)Army Medical University(CN)Wenzhou Medical University(CN)Zhejiang Cancer Hospital(CN)Jiaxing Vocational Technical College(CN)Guangdong Urban & Rural Planning and Design Institute(CN)Cancer Hospital of Chinese Academy of Medical Sciences(CN)Guangdong Academy of Medical Sciences(CN)University of Chinese Academy of Sciences(CN)Hangzhou Cancer Hospital(CN)Ocean University of China(CN)
Publications by Year
Research Areas
Head and Neck Cancer Studies, Lung Cancer Treatments and Mutations, Head and Neck Surgical Oncology, Lung Cancer Research Studies, Cancer Immunotherapy and Biomarkers
Most-Cited Works
- → Gemcitabine plus cisplatin versus fluorouracil plus cisplatin in recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 trial(2016)520 cited
- → Camrelizumab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (CAPTAIN-1st): a multicentre, randomised, double-blind, phase 3 trial(2021)439 cited
- → Toripalimab or placebo plus chemotherapy as first-line treatment in advanced nasopharyngeal carcinoma: a multicenter randomized phase 3 trial(2021)392 cited
- → The Chinese Society of Clinical Oncology (CSCO) clinical guidelines for the diagnosis and treatment of nasopharyngeal carcinoma(2021)381 cited
- → Concurrent chemoradiotherapy with/without induction chemotherapy in locoregionally advanced nasopharyngeal carcinoma: Long‐term results of phase 3 randomized controlled trial(2019)244 cited